Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DNLI Stock Forecast 2026-2027
$20.57
Current Price
$3.26B
Market Cap
Buy 18
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to DNLI Price Targets
+104.2%
To High Target of $42.00
+92.0%
To Median Target of $39.50
+21.5%
To Low Target of $25.00
DNLI Price Momentum
+5.9%
1 Week Change
+2.0%
1 Month Change
+61.5%
1 Year Change
+24.6%
Year-to-Date Change
-13.5%
From 52W High of $23.77
+67.1%
From 52W Low of $12.31
📊 TOP ANALYST CALLS
Did DNLI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Denali is one of their latest high-conviction picks.
Latest DNLI Stock Price Targets & Analyst Predictions
Based on our analysis of 26 Wall Street analysts, DNLI has a bullish consensus with a median price target of $39.50 (ranging from $25.00 to $42.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $20.57, the median forecast implies a 92.0% upside. This outlook is supported by 18 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matthew Harrison at Morgan Stanley, projecting a 104.2% upside. Conversely, the most conservative target is provided by Michael Yee at UBS, suggesting a 21.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DNLI Analyst Ratings
18
Buy
1
Hold
0
Sell
DNLI Price Target Range
Low
$25.00
Average
$39.50
High
$42.00
Current: $20.57
Latest DNLI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DNLI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 7, 2026 | Baird | Joel Beatty | Outperform | Maintains | $34.00 |
| Mar 26, 2026 | Stifel | Paul Mattels | Buy | Maintains | $41.00 |
| Mar 26, 2026 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $42.00 |
| Mar 26, 2026 | Goldman Sachs | Salveen Richter | Buy | Maintains | $40.00 |
| Mar 26, 2026 | Baird | Joel Beatty | Outperform | Maintains | $32.00 |
| Mar 26, 2026 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $42.00 |
| Mar 25, 2026 | BTIG | Thomas Shrader | Buy | Maintains | $38.00 |
| Mar 2, 2026 | BTIG | Thomas Shrader | Buy | Maintains | $36.00 |
| Feb 24, 2026 | Wolfe Research | Rudy Li | Peer Perform | Initiates | $N/A |
| Feb 6, 2026 | BTIG | Thomas Shrader | Buy | Reiterates | $32.00 |
| Jan 7, 2026 | UBS | Michael Yee | Buy | Assumes | $25.00 |
| Dec 11, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $30.00 |
| Dec 5, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $31.00 |
| Dec 5, 2025 | BTIG | Thomas Shrader | Buy | Reiterates | $32.00 |
| Nov 4, 2025 | JP Morgan | Jessica Fye | Overweight | Maintains | $26.00 |
| Sep 8, 2025 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $N/A |
| Aug 18, 2025 | Morgan Stanley | Matthew Harrison | Overweight | Maintains | $30.00 |
| May 19, 2025 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $27.00 |
| May 8, 2025 | Baird | Joel Beatty | Outperform | Maintains | $29.00 |
| May 7, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $30.00 |
Denali Therapeutics Inc. (DNLI) Competitors
The following stocks are similar to Denali based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Denali Therapeutics Inc. (DNLI) Financial Data
Valuation Metrics
Market Cap
$3.26B
Enterprise Value
$2.44B
P/E Ratio
N/A
PEG Ratio
-8.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+26.6%
Current Ratio
9.2x
Debt/Equity
4.2x
ROE
-45.7%
ROA
-27.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Denali Therapeutics Inc. (DNLI) Business Model
About Denali Therapeutics Inc.
What They Do
Develops therapeutics for neurodegenerative diseases.
Business Model
The company utilizes proprietary technologies to engineer product candidates that enable effective delivery of therapies across the blood-brain barrier. Denali generates revenue by advancing its pipeline programs through clinical development and ultimately seeks to commercialize successful therapies targeting neurodegenerative and lysosomal storage diseases.
Additional Information
Founded in 2013 and based in South San Francisco, Denali Therapeutics is positioned in the biotechnology sector with a focus on addressing unmet medical needs in neurology and rare genetic disorders. Their extensive pipeline includes multiple programs targeting conditions such as Hunter syndrome, Sanfilippo Syndrome A, amyotrophic lateral sclerosis, and Parkinson's disease, showcasing a commitment to innovation in healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
517
CEO
Dr. Ryan J. Watts Ph.D.
Country
United States
IPO Year
2017
Website
www.denalitherapeutics.comDenali Therapeutics Inc. (DNLI) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
DNLI secures FDA nod for Avlayah, a first-in-decades Hunter syndrome therapy, but pipeline risks and Takedas exit complicate the outlook.
Apr 17, 2026
By Zacks Equity Research
Analyst Blog
Denali Stock Falls as Partner Takeda Ends Collaboration Deal
DNLI's shares decline after Takeda exits DNL593 partnership, leaving Denali to fully control and fund the therapy as it advances studies and plans 2026 data release.
Apr 07, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
DNLI received FDA approval for Avlayah, a new therapy for Hunter syndrome. However, pipeline risks and Takeda's exit may affect future prospects.
Why It Matters
DNLI's FDA approval for Avlayah opens a new revenue stream but pipeline risks and Takeda's exit raise concerns about future growth and stability, impacting investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Denali (DNLI) shares fell as Takeda ended its partnership on DNL593, transferring full control and funding of the therapy to Denali, which aims for data release in 2026.
Why It Matters
DNLI's share decline signals increased financial burden and risk due to full control of DNL593 after Takeda's exit, impacting future funding and study outcomes.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Takeda has terminated its collaboration agreement with Denali Therapeutics for the co-development of DNL593, a therapy aimed at frontotemporal dementia.
Why It Matters
The termination of the collaboration may impact Denali's pipeline and revenue potential, raising concerns about its financial stability and future stock performance.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
Denali Therapeutics (Nasdaq: DNLI) announced the termination of its collaboration with Takeda on DNL593, an investigational treatment for frontotemporal dementia. Denali will regain full control of DNL593.
Why It Matters
Denali regaining full control of DNL593 after Takeda's termination of the collaboration may impact its strategic direction, financial outlook, and potential for future partnerships or funding.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Denali Solved A Major Challenge In Treating A Rare Genetic Disease. Now, Shares Are Flying.
19 days ago
Quick Summary
Denali Therapeutics has addressed a significant hurdle in Hunter syndrome treatment and is poised to advance its technology further.
Why It Matters
Denali Therapeutics' breakthrough in Hunter syndrome treatment could lead to new revenue streams and increased market confidence, impacting stock performance and investor interest.
Source: Investors Business Daily
Market Sentiment:
Neutral
Quick Summary
Denali Therapeutics received FDA approval for a new drug to treat a rare genetic disease, marking the first new treatment in 20 years in this category.
Why It Matters
FDA approval of Denali Therapeutics' drug opens revenue streams and boosts market confidence, potentially increasing stock value and attracting investor interest in biotech.
Source: Investors Business Daily
Market Sentiment:
Positive
Frequently Asked Questions About DNLI Stock
What is Denali Therapeutics Inc.'s (DNLI) stock forecast for 2026?
Based on our analysis of 26 Wall Street analysts, Denali Therapeutics Inc. (DNLI) has a median price target of $39.50. The highest price target is $42.00 and the lowest is $25.00.
Is DNLI stock a good investment in 2026?
According to current analyst ratings, DNLI has 18 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $20.57. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DNLI stock?
Wall Street analysts predict DNLI stock could reach $39.50 in the next 12 months. This represents a 92.0% increase from the current price of $20.57. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Denali Therapeutics Inc.'s business model?
The company utilizes proprietary technologies to engineer product candidates that enable effective delivery of therapies across the blood-brain barrier. Denali generates revenue by advancing its pipeline programs through clinical development and ultimately seeks to commercialize successful therapies targeting neurodegenerative and lysosomal storage diseases.
What is the highest forecasted price for DNLI Denali Therapeutics Inc.?
The highest price target for DNLI is $42.00 from Matthew Harrison at Morgan Stanley, which represents a 104.2% increase from the current price of $20.57.
What is the lowest forecasted price for DNLI Denali Therapeutics Inc.?
The lowest price target for DNLI is $25.00 from Michael Yee at UBS, which represents a 21.5% increase from the current price of $20.57.
What is the overall DNLI consensus from analysts for Denali Therapeutics Inc.?
The overall analyst consensus for DNLI is bullish. Out of 26 Wall Street analysts, 18 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $39.50.
How accurate are DNLI stock price projections?
Stock price projections, including those for Denali Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 12:50 PM UTC